What is Amneal Pharmaceuticals, Inc.'s specialty — SG&A?

Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — SG&A of $40.1M in Q2 2026.

How has Amneal Pharmaceuticals, Inc.'s specialty — SG&A changed year-over-year?

Amneal Pharmaceuticals, Inc.'s specialty — SG&A increased by 32.3% year-over-year, from $30.31M to $40.1M.

What does specialty — SG&A mean?

Encompasses the overhead costs associated with operating the specialty segment, including salesforce compensation, marketing, and general administrative support. This metric reflects the operational intensity and investment required to maintain and grow the segment's market presence.

Amneal Pharmaceuticals, Inc. (AMRX) Specialty — SG&A

Screener

Other segment segments

Affordable Medicines

$42.37M+23.8%

AvKARE

$16.91M+12.2%

Similar metrics at other companies

IAR

IARTSpecialty Surgery — SG&A

$75.98M-8.6%

KLACSpecialty Semiconductor Process — SG&A

$12.51M+15.2%

LENCentral — SG&A

$148.21M-2.7%

LENEast — SG&A

$162.77M+0.4%

LENHomebuilding — SG&A

$617.5M+0.3%

LENOther — SG&A

$7.71M+91.6%

Other financials

Income statement

See full

Revenue$796.2M+9.9%

Gross profit$334.5M+16.9%

Operating income$129.8M+16.5%

Net income$57.7M+157%

EPS (diluted)$0.18+157%

Balance sheet

See full

Cash & equivalents$127.6M+78.4%

Total debt$2.6B+18.0%

Total equity$33.0M+129%

Total assets$3.8B+10.3%

Cash flow

See full

Operating cash flow-$21.2M-125%

CapEx$30.7M+34.5%

Free cash flow-$51.9M-185%

Valuation

See full

Market cap$5.77B+129%

Enterprise value$8.21B+77.4%

P/E36.7×-711×

P/S1.9×+1.0×

Profitability

See full

Gross margin39.3%+1.7pp

Operating margin14.6%+1.4pp

Net margin5%+4.9pp

FCF margin4.1%-5.8pp

Returns & leverage

See full

Return on equity-52.8%-12.7pp

Debt / equity77.8×—

Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed: Aug 6, 2026, 5:19 PM EDT
Fiscal quarter: Q2 FY2026
Calendar quarter: Q2 2026
Accession: 0001723128-26-000031

Three Months Ended June 30, 2026	Affordable Medicines (1)	Specialty	Av KARE	Corporateand Other	Total Company
Net revenue	$489,913	$149,295	$156,989	—	$796,197
Cost of goods sold	282,684	48,265	130,740	—	461,689
Gross profit	207,229	101,030	26,249	—	334,508
Selling, general and administrative	42,367	40,095	16,913	49,347	148,722
Research and development	33,023	5,994	—	—	39,017
Intellectual property legal development expenses	2,002	85	—	—	2,087
Acquisition costs	—	—	—	7,600	7,600
Restructuring and other charges	—	—	—	554	554

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s specialty — SG&A?: Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — SG&A of $40.1M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s specialty — SG&A changed year-over-year?: Amneal Pharmaceuticals, Inc.'s specialty — SG&A increased by 32.3% year-over-year, from $30.31M to $40.1M.
What does specialty — SG&A mean?: Encompasses the overhead costs associated with operating the specialty segment, including salesforce compensation, marketing, and general administrative support. This metric reflects the operational intensity and investment required to maintain and grow the segment's market presence.